Search

everythinglearnresearchcommunity

for

Search:↓

New treatments for prostate cancer are less toxic and show promise, but more research is needed to enhance their effectiveness and reduce side effects.

PM-9 and finasteride effectively inhibit the enzyme that converts testosterone to DHT.

The treatment improved hair growth and was well-received without side effects.

Ritlecitinib helped most alopecia areata patients regrow hair by Week 48.

New pyrazole-based inhibitors show promise for treating metabolic diseases and other conditions.

Antiandrogens affect androgen-dependent body functions and are used for various medical conditions, with some risks like fetus feminization, but new forms like 17α-propylmesterolone show promise for acne without systemic effects.

STS01 1% effectively promotes hair regrowth with minimal side effects.

Using 5-alpha reductase inhibitors may lower prostate cancer risk in people with androgenetic alopecia.

Cyproterone acetate can effectively treat idiopathic hirsutism, but ethinyl oestradiol and lynoestrenol may not always reduce hair growth.

New steroid compounds may help with hormonal therapy and have potential benefits for glucose disorders, but more research is needed.

Finasteride and dutasteride reduce prostate cancer risk, but finasteride may increase higher-grade cancer risk.

Serenoa repens may cause long-lasting sexual and psychiatric side effects.

Both finasteride and drospirenone treatments improved symptoms and increased pregnancy rates in women with polycystic ovary syndrome.

Selective non-steroidal inhibitors of 5α-reductase type 1 can help treat DHT-related disorders.

α-MSH increases melanin production in moulting hair follicles, while AVT inhibits it.

Clascoterone cream was approved in the USA for treating acne in people aged 12 and older.

The compound (1R,2S)-4-(2-Cyano-cyclohexyl-oxy)-2-trifluoromethyl-benzonitrile can stimulate hair growth and reduce oil production when applied topically.

DS-2325a is safe and well-tolerated, supporting further development for Netherton Syndrome treatment.

Lifestyle changes are more effective than medication for managing PCOS-related risks.

A new compound may treat benign prostatic hyperplasia better than finasteride.

Canagliflozin helps overcome progestin resistance in certain endometrial cancer cells.

Synthetic 19-norprogestins promote bone cell growth and function through their non-phenolic metabolites.

Researchers developed new compounds that target the androgen receptor effectively with fewer side effects.

Ponatinib can cause a rare skin reaction that resolves with topical treatment and temporary drug discontinuation.

Pregnenolone might help manage movement issues caused by Parkinson's disease treatment without reducing the medicine's effectiveness.

5α-reductase inhibitors, like Finasteride and Dutasteride, help manage benign prostatic hyperplasia.

Cortexolone 17a-propionate may be an effective new treatment for hair loss.

A new psoriasis lotion called "Psorisbye" improved symptoms in a patient within one week.